Tumor budding as a standardized parameter in gastrointestinal carcinomas: more than just the colon

Abstract

Tumor budding, defined as single cells or clusters of less than five cells, is thought to be a histomorphologic marker of an aggressive tumor behavior mimicking the embryologic epithelial–mesenchymal transition, and has been well established in the past two decades as a poor prognostic factor in colorectal carcinoma. Slow uptake in routine reporting of this important pathologic prognostic feature was in part due to differing methods of assessment of budding reported in the literature, but has recently been clarified at a consensus conference on tumor budding in colorectal carcinoma. Tumor budding is also increasingly being reported as a useful pathologic prognostic feature in other gastrointestinal carcinomas, including esophageal squamous cell carcinoma and adenocarcinoma, gastric intestinal-type adenocarcinoma, pancreatic ductal adenocarcinoma, and ampullary adenocarcinoma. In this review, we will summarize the studies on tumor budding in gastrointestinal carcinomas, with a focus on the methods of assessment used and the potential clinical applications of the findings.

In a time of ever increasing molecular scrutiny of cancers, histomorphologic analysis remains an important tool to stratify malignant lesions. Tumor budding, defined by single cells or small clusters of cells, has been well established in the past two decades as a poor prognostic factor for colorectal adenocarcinoma, but has been slow to be incorporated into routine pathology reporting. However, the most recent AJCC 8th edition, as well as the College of American Pathologists guidelines for colorectal carcinoma reporting, are now including tumor budding as an optional reporting field with a recommendation to report in all stage I and stage II cases, in part following an international consensus conference, which provided us with a standardized reporting tool for tumor budding in colorectal carcinoma [1]. Tumor budding, however, is not unique to colorectal carcinoma and more recently has been gaining attention as a prognostic factor in a number of other gastrointestinal malignancies. Here, we will review the significance of tumor budding as a prognostic factor, with a focus on the methods of assessment used and the potential clinical applicability of the results, in gastrointestinal carcinomas, including the esophagus, stomach, pancreas, ampulla of Vater, and colon.

Toward a standardized assessment of tumor budding

The first description of what we now call tumor budding was by Imai in the 1950s, as “sprouting” at the invasive edge of carcinomas [2]. Since then, tumor budding has been shown to be a histopathologic marker of an aggressive tumor biologic process. Tumor buds in colorectal carcinoma show downregulation of adhesion protein E-cadherin, accompanying nuclear translocation of beta-catenin, and loss of cell polarity with acquisition of a fibroblastoid morphology [3]. One prevalent hypothesis has been that tumor budding mimics the epithelial–mesenchymal transition, a normal process involved in embryologic development and wound healing, whereby cells reduce intercellular adhesion proteins and acquire a mesenchymal phenotype capable of migration [3, 4]. Colorectal carcinoma tumor buds have been shown to have upregulation of mesenchymal markers, and of known inducers of the epithelial–mesenchymal transition such as transcription factors ZEB1 and ZEB2 [4]. Another hypothesis suggests that although tumor buds exhibit E-cadherin downregulation, they do not share other regulatory changes common to the epithelial–mesenchymal transition and that the budding phenotype may occur by another mechanism [5, 6].

A study by Hase et al. in 1993 first adopted the phrase “tumor budding”, and showed a dramatic decrease in survival with increased budding in colorectal carcinoma (5-year survival of 22 vs. 71%, p < 0.001) [7]. This first definition of budding by Hase was subjective, with budding defined as small clusters of cells at the invasive front, and budding classified into none or mild (BD-1) and moderate or severe (BD-2) (Fig. 1).

Fig. 1
figure1

Tumor budding in gastrointestinal carcinomas, with arrows to indicate budding foci. a Colorectal carcinoma (hematoxylin and eosin, ×200). b Esophageal squamous cell carcinoma (hematoxylin and eosin, ×200). c Gastric intestinal-type adenocarcinoma (hematoxylin and eosin, ×200). d Pancreatic ductal adenocarcinoma (hematoxylin and eosin, ×200).

Over the past two decades, numerous methods of assessing tumor budding have been proposed, with variations in the area of assessment, cutoff values, and use of standard hematoxylin and eosin stained slides vs. cytokeratin immunohistochemistry. One of the first quantitative, and more popular, methods was proposed by Ueno et al. [8] in a study looking at pathologic prognostic features of pT1 colorectal carcinoma. Their group defined tumor buds as single cells or clusters of <5 cells, counted buds in the area of maximal budding using a ×250 (0.385 mm2) field, and then classified patients into negative budding (<10 buds) and positive budding (≥10 buds). A subsequent study by Ueno et al. [9] used a modified method, counting budding in a ×200 (0.785 mm2) field, with five buds as the cutoff for high-grade budding. Another popular method of budding assessment was outlined by Karamitopolou et al. [10] in their study on pancreatic ductal adenocarcinoma, using a cytokeratin stain to highlight budding and averaging bud counts over 10 high power fields (hpf). One multicenter study has looked at reproducibility of tumor budding assessments on hematoxylin and eosin vs. cytokeratin staining, using the Ueno and Hase methods in addition to two other methods [11, 12], on a set of 50 colorectal carcinoma cases [13]. The reproducibility was fair overall, and although cytokeratin staining increased tumor budding counts (partially by detection of single cells in glands disrupted by inflammatory cells), it did not increase the agreement between observers (Ueno methods hematoxylin and eosin k = 0.35/0.34 and immunohistochemistry k = 0.26/0.34) [13].

There has also been variation in the area in which tumor budding is assessed. Most studies have used the “hotspot method”, as was used in the Ueno study [8, 9], whereby the pathologist decides on a single field that displays maximal budding to perform the count. This choice of field, however, may introduce variability. Other studies have examined multiple fields, ranging from assessment of the entire invasive front, to bud counts in 5–10 fields with use of the average count [10,11,12]. However, in the same multicenter study of tumor budding reproducibility, both the Ueno (hotspot) and the Wang (average of 5 hpf) methods had comparable interobserver variability (k = 0.35 vs. 0.25) [13].

The concept of whether “peritumoral” vs. “intratumoral” tumor budding, or both, should be assessed is still under discussion. The original studies on tumor budding, in pT1 colorectal carcinoma, utilized “peritumoral” budding, or assessment of budding at the invasive front of the carcinoma [7, 8]. In the case of a malignant polyp, or pT1 colorectal carcinoma, this makes sense as the specimen is small and the invasive front is usually clear. However, the delineation of an invasive front in a biopsy or in a resection for pancreatic ductal adenocarcinoma, for example, would be difficult and poorly reproducible. Therefore, the idea of intratumoral budding was introduced in 2011, in the context of preoperative biopsies of colorectal carcinoma [14]. Intratumoral budding has been defined as clusters of less than five cells surrounded by tumor stroma within the tumor bulk. Giger et al. [14] showed intratumoral budding in the biopsy and peritumoral budding in the resection to be similarly reproducible (k = 0.65 vs. k = 0.68), and to be significantly associated. Since then the concept of intratumoral budding has been applied in pancreatic ductal adenocarcinoma and esophageal squamous cell carcinoma.

The Ueno method, with some modifications, was the standardized method chosen at a recent consensus conference on the reporting of tumor budding in colorectal carcinoma [1]. The consensus definition of tumor budding was as follows based on use of hematoxylin and eosin staining: single cells or clusters of <5 cells, counted in the area of maximal budding (“hotspot method”) at a ×200 field (then normalized to a 0.785 mm2 field), with patients then classified as low grade (0–4 buds), intermediate (5–9 buds), and high-grade budding (≥10 buds). To minimize variability in selecting the field of maximal budding, they suggest screening at least 10 hpf at the invasive front. Although it was felt that intratumoral budding is likely also a useful prognostic factor, it was recommended that more research is needed before incorporation into routine practice. These were the recommendations for colorectal carcinoma, however, the optimal method for assessing tumor budding, and especially the optimal cutoff values, may vary in different sites of the gastrointestinal tract, and the different methods used in these malignancies will be discussed with the studies.

Colorectal adenocarcinoma

Tumor budding has been well established as a poor prognostic factor in colorectal carcinoma, with two well-studied clinical applications [15], and will be reviewed briefly here.

Early stage colorectal carcinoma, detected in polypectomy specimens as pT1 colorectal cancer, has the potential to be cured with polypectomy alone, although ~9–24% of these patients have lymph node metastases [9, 16,17,18,19,20,21,22,23]. High-grade tumor budding has been well established as one of the pathologic prognostic criteria that carry increased risk for lymph node metastases and, therefore, need for surgery post polypectomy (see Table 1) [7,8,9, 21, 23]. In a systematic review of 17 studies on the risk of lymph node metastases in pT1 colorectal carcinoma based on pathologic prognostic factors, tumor budding (investigated in seven studies) was found to be a significant risk factor for lymph node metastases, in addition to lymphatic invasion and submucosal invasive depth of >1 mm [24]. Tumor budding carried a relative risk of 5.1 (3.6–7.3) for lymph node metastasis, and was an independent predictive factor in five of the six studies that performed a multivariate analysis. The Japanese Society for Cancer of the Colon and Rectum has incorporated tumor budding into the guidelines for which pT1 carcinoma patients require subsequent surgery (along with vascular invasion, high grade, and submucosal depth of invasion >1000 µm), using the consensus method for assessment of budding, and applying a cutoff of 5 or more (intermediate and high-grade categories) as high risk [25].

Table 1 Summary of key studies on tumor budding in pT1 and stage II colorectal carcinoma

Stage II colorectal carcinoma encompasses a group of patients with T3–T4 tumors, and no lymph node metastases. Although some of these patients are cured with surgery, a subset of these patients have substantial risk of recurrence (5-year survival rates of 45–67%, SEER database) [26]. Tumor budding has been well established as a poor prognostic factor in stage II colorectal carcinoma (see Table 1) [27, 28]. A recent systematic review of 12 studies assessing tumor budding as a prognostic factor in stage II colorectal carcinoma showed high-grade budding to be a significant poor prognostic factor with an odds ratio of 6.25 for mortality (4.04–9.67, p < 0.00001) and to be an independent predictor of mortality (HR: 3.68, 2.16–6.26, p < 0.00001) [29]. Tumor budding should be routinely reported in stage II CRC in order to aid in the decision for adjuvant therapy (utilizing a cutoff value of 10, or high grade, per the consensus conference) along with other known predictive factors including mismatch repair status [1].

More recently, tumor budding has been studied in preoperative biopsies of colonic masses as a potential predictive factor for lymph node metastases, although the criteria for this application are unclear [14, 30, 31]. The methods for assessing tumor budding in these studies have been substantially different, using qualitative assessment of presence/absence of budding at low power vs., at the opposite end of the spectrum, quantitative assessment of budding using a cytokeratin stain at high power. All of these studies showed a significant association with lymph node metastases however, and hopefully future larger studies may standardize the approach to grading tumor budding in preoperative biopsies in order to establish budding as a clinical useful decision factor.

High-grade tumor budding has also been reported to predict non-responders to anti-EGFR therapies, along with K-Ras mutation status [32]. Of interest in that study, low-grade tumor budding was 100% predictive of response to EGFR therapy, with all low-grade budding having at least partial response, and no progressive or even stable disease [32].

Esophageal squamous cell carcinoma and adenocarcinoma

Multiple studies have now associated high-grade tumor budding with a poor prognosis for esophageal squamous cell carcinoma (see Table 2 for summary), and more recently tumor budding has been incorporated into a grading system for esophageal squamous cell carcinoma. The majority of the studies on esophageal squamous cell carcinoma have utilized a modified Ueno method, defining tumor budding to be single cells to clusters of <5, counted in the area of maximal budding at ×200 and classified into low-grade/rare budding (<5 buds) and high-grade/frequent budding (≥5 buds).

Table 2 Tumor budding studies in esophageal squamous cell carcinoma

The significance of tumor budding as a poor prognostic factor in cohorts of all patients undergoing esophagectomy for esophageal squamous cell carcinoma has been replicated in multiple studies. Roh et al. [33] first studied a cohort of 56 patients (39% low-grade/61% high-grade budding), and found the 3-year survival rate to be significantly lower in high-grade budding (30.7 vs. 72.3%, p = 0.04). Tumor budding was independent of differentiation, but was associated with larger tumor size. Another group replicated these findings in a larger cohort of 136 patients (40% low-grade/60% high-grade budding) [34]. The 3- and 5-year survival rates for the high-grade group (43, 35%) were significantly higher than the low-grade group (92, 81%, p < 0.001). Lymph node metastases, lymphovascular invasion, and higher T stage were all significantly associated with high-grade budding. By multivariate analysis, tumor budding (HR: 4.195, 1.77–9.941) and lymph node metastases (HR: 4.682) were found to be independent prognostic factors. More recently, a smaller cohort of 82 patients (44% low-grade/56% high-grade budding) showed significantly lower disease-free survival in the high-grade budding group (p < 0.0001) with a trend toward decreased overall survival [35]. These studies have speculated on, but not directly addressed, the use of high-grade tumor budding in the decision for adjuvant therapy, but future studies are required to investigate this potential application.

One small cohort study (n = 74) has shown tumor budding in the esophagectomy specimen to maintain its value as a significant prognostic factor even after neoadjuvant chemotherapy [36]. High-grade budding was correlated with a significantly lower 5-year survival (17 vs. 58%, p < 0.001). This study also correlated tumor budding with neoadjuvant response, dividing patient based on clinical staging into complete response, partial response, and no response. Promisingly, high-grade budding was found to be significantly less common in responders to neoadjuvant therapy than non-responders (p = 0.001), and this raises the potential that tumor budding might be useful as a predictive marker of response to neoadjuvant therapy. However, as the tumor budding analysis was limited to the final resection specimen without assessment of the biopsy, this remains a question for a future study.

Tumor budding in pT1 esophageal squamous cell carcinoma has been investigated in one study, in an attempt to determine factors that might allow some T1 patients to be treated with local endoscopic methods only [37]. The cohort of 79 patients who underwent esophagectomy for T1 carcinoma were divided into low-grade budding (<3 buds, 64%) and high-grade (≥3 buds, 37%). The 3-year survival for the high-grade group (48.8%) was significantly lower than in the low-grade group (94.5%, p < 0.001). By multivariate analysis, high-grade tumor budding was an independent poor prognostic factor (HR: 4.42, 1.08–18.18). Future studies might help to investigate the value of budding in this clinical application, as has been shown for colorectal carcinoma.

More recently, Jesinghaus et al. [38] have included tumor budding in their novel grading system for esophageal squamous cell carcinoma. The system assesses tumor budding and cell nests, using the entire tumor area (both intratumoral and peritumoral budding), and is based on the grading scheme they recently previously proposed and validated in both lung and oral squamous cell carcinoma [39, 40]. Their cell nest parameter, defined by clusters of more than five tumor cells surrounded by tumor stroma and evaluated in the area of smallest nest size, does partially overlap with tumor budding but is meant to provide additional information about tumor invasiveness. In a cohort of 135 patients who underwent esophagectomy for squamous cell carcinoma, tumor budding activity was scored as 1 (no budding), 2 (1–15 buds per 10 hpf), and 3 (≥15 buds per 10 hpf) and cell nests were scored as 1 (>15 cells), 2 (5–15 cells), 3 (2–4 cells), and 4 (single cells); with the sum giving a total score. Patients were then classified as grade 1 (score 2–3, 24%), which had a 117-month disease-free survival, grade 2 (score 4–5, 28%) with a 76-month disease-free survival, and grade 3 (score 6–7, 48%) with a 35-month disease-free survival. Promisingly, the novel grading system was independent of stage for overall survival by multivariate analysis, and it is hopeful that this may become the new standard.

Only one study to date has investigated tumor budding in esophageal adenocarcinoma [41]. Their retrospective cohort included 162 patients with esophageal adenocarcinoma that underwent esophagectomy. Tumor budding (single cells to clusters of ≤5) was counted at the invasive front (peritumoral) and within the tumor (intratumoral) in 10 hpf with a cytokeratin stain, and the median (130) was used to classify into low- and high-grade budding. High-grade intratumoral budding (not peritumoral) was associated with a significantly decreased overall survival in this cohort.

Gastric adenocarcinoma

Only in the last few years has tumor budding been investigated as a potential prognostic factor in gastric adenocarcinoma. Tumor budding in gastric adenocarcinoma is only assessed in the well-differentiated/intestinal subtype, as the undifferentiated/diffuse type by definition displays tumor budding.

Early gastric adenocarcinomas (T1a) have the potential to be treated and cured with endoscopic mucosal resection or endoscopic submucosal dissection alone, with current criteria including size <2 cm without ulceration, intestinal type, and absence of lymphovascular invasion; however, currently T1b gastric adenocarcinomas are all treated with subtotal or total gastrectomy without consideration for local therapy [42]. A study by Gulluoglu et al. [43] assessed the ability of tumor budding to predict lymph node metastases in 126 T1 gastric adenocarcinomas that had undergone gastrectomy. They used a different method for assessing budding than any other study reviewed here, looking for budding (single cells or clusters of <5) at the invasive front, and counting the patient as budding positive if any buds were seen at ×400 (31% of 126 cases). They found that tumor budding positivity was significantly more common in lymph node positive vs. node negative patients with pT1b carcinomas (76 vs. 24%, p < 0.001), and suggest with further study it may be one criterion could stratify T1b patients into low-risk candidates to undergo local treatment.

The utility of tumor budding as a general poor prognostic factor in cohorts of all patients undergoing gastrectomy has been replicated in three studies, all using different methods of budding assessment. A cohort of 52 gastric intestinal-type adenocarcinomas was assessed using budding counts in ten ×200 fields, with an average count of ≥1 bud per field considered positive for high-grade budding (63% of cases) [44]. High-grade tumor budding was significantly associated with lymph node metastasis (55 vs. 5%, p < 0.001). A larger cohort of 153 well-differentiated gastric adenocarcinomas was assessed using an average bud count over at least three ×400 fields in the area of maximal budding using a cytokeratin stain, with 10 buds per hpf as the cutoff for high-grade budding as determined by their receiver operating characteristic (ROC) curve. High-grade tumor budding was significantly associated with decreased overall survival (HR: 1.61, 1.12–2.41, p < 0.01). A third study with a cohort of 296 patients with any T stage gastric adenocarcinoma showed a decreased overall survival (HR: 2.260, 1.617–3.159) with high-grade budding, however, this study had a combined cohort of intestinal and diffuse-type adenocarcinoma so interpretation of their results is difficult due to the confounding factor of known poor prognosis for diffuse-type vs. intestinal-type adenocarcinoma [45].

Ampullary carcinoma

Ampullary carcinoma is a rare gastrointestinal carcinoma with a wide range in expected survival rates, and tumor budding has been reported to be an independent prognostic factor [46]. One study to date has looked at tumor budding as a prognostic indicator in ampullary adenocarcinomas, using a multi-institutional cohort of 244 patients with true primary ampullary adenocarcinomas (epicenter in the ampulla or major papilla, or involving the papilla-Vater mucosa) [46]. A modified Ueno method to assess budding was used, defining high-grade budding to be an average of ≥3 buds per ×200 field (80% of cases). Patients with high-grade budding had increased lymph node metastases (44 vs. 17%, p < 0.001), and decreased 3- and 5-year survival rates (41 and 24% vs. 93 and 68% for low-grade budding, p < 0.001).

Pancreatic ductal adenocarcinoma

Although pancreatic cancer represents only 3% of malignancies overall, it has an extremely poor prognosis, and is the fourth leading cause of cancer death [47]. There is a need to identify patients that might respond to aggressive treatment. Tumor budding has been investigated in multiple studies now as a prognostic marker in pancreatic ductal adenocarcinoma (see Table 3 for summary). All studies on budding in pancreatic ductal adenocarcinoma have not distinguished between peritumoral budding and intratumoral budding due to the difficulty and poor reproducibility in determining the invasive front, and the methods for assessing tumor budding have differed.

Table 3 Summary of tumor budding studies in pancreatic ductal adenocarcinoma

Tumor budding in pancreatic ductal adenocarcinoma was first investigated by Karamitopoulou et al. [10] in a cohort of 117 patients, using cytokeratin staining to count tumor budding in 10 hpf, and selecting ≥10 buds per hpf as the cutoff for high-grade budding by receiver operating characteristic curve analysis. High-grade budding had a dramatic impact on survival, with a 1-year survival rate of 28% for high-grade budding vs. 86% for low-grade budding. By multivariate analysis of overall survival, tumor budding was the most powerful prognostic factor (HR: 3.98, 2.3–6.9), greater than TMN stage (HR: 1.2). This was replicated in a cohort of 192 pancreatic ductal adenocarcinoma patients, counting tumor budding on hematoxylin and eosin staining in 10 hpf, and classified budding into absent (12% of cases), low grade (<10 buds per 10 hpf, 17% of cases), or high grade (>10 buds per 10 hpf, 71% of cases) [48]. High-grade budding was significantly associated with a poorer prognosis, with disease-specific survival rates of 1.24 year (high grade) vs. 1.42 year (low grade, p = 0.039).

The biologic basis for tumor budding in pancreatic ductal adenocarcinoma, and its similarity to that seen in colorectal carcinoma, has also been studied. Kohler et al. [49] studied a cohort of 108 patients with pancreatic ductal adenocarcinoma of the pancreatic head who had not received neoadjuvant therapy, using the Karamitopolou method. High-grade tumor budding was seen in 70% of cases, with a trend toward decreased survival that did not reach significance (p = 0.07). Interestingly however, this group also looked at loss of e-cadherin expression as a biologic marker of epithelial–mesenchymal transition, and found e-cadherin expression to be significantly lower in areas of tumor budding (23 vs. 88%, p < 0.0001). More recently, the expression of e-cadherin and microRNAs in a small subset of pancreatic ductal adenocarcinomas exhibiting tumor budding was analyzed, using non-budding pancreatic ductal adenocarcinomas as a control [50]. Pancreatic ductal adenocarcinomas exhibiting tumor budding had decreased expression of e-cadherin, increased expression of e-cadherin suppressive regulatory factors ZEB1 and ZEB2, and corresponding downregulation in miR-200 family miRNAs, which have been shown to function in growth suppression.

One group has looked at the association between FOXP3 + regulatory T cells and high-grade tumor budding in a group of 120 patients with pancreatic ductal adenocarcinoma, using the Karamitopolou method [51]. Increased regulatory T cell counts were significantly associated with high-grade tumor budding (p = 0.04), and worse prognosis by univariate analysis (p = 0.03).

While tumor budding has now been well established as a poor prognostic factor in pancreatic ductal adenocarcinoma, clinically relevant applications to the management of patients have not been established. Part of the difficulty lies in the differing methods of budding assessment used in the studies, and hopefully consensus can be achieved in pancreatic ductal adenocarcinoma as has been done for colorectal carcinoma. Studies on tumor budding in pancreatic ductal adenocarcinoma have speculated that tumor budding in pancreatic ductal adenocarcinoma may be useful in selecting the small number of patients that may benefit from more aggressive treatment, and uniform reporting of budding may help with future studies and to develop this potential important clinical application [49].

Conclusions

Tumor budding is emerging as an important histomorphologic marker of an aggressive tumor behavior in the majority of gastrointestinal carcinomas. We are now in the fortunate situation to have a standardized scoring system for colorectal carcinoma that will hopefully allow for comparative studies to demonstrate meaningful and standardized assessment methods and cutoff values for tumor budding in other gastrointestinal carcinomas. Only robust clinically annotated samples assessed for tumor budding will allow for exact substratification of patients, and as such it is of utmost importance to confirm and reproduce cutoff counts of this important histomorphologic parameter.

This review aims to serve as summary of the current state-of-tumor budding along the entire gastrointestinal tract. With respect to colorectal carcinoma, pathologists should now be routinely assessing tumor budding utilizing the consensus method in both pT1 and stage II colorectal carcinoma. In regard to esophageal squamous cell carcinoma, well-differentiated gastric adenocarcinoma, ampullary adenocarcinoma, and pancreatic ductal adenocarcinoma, multiple potential clinical applications for tumor budding have been studied and reviewed here. It will require awareness of these studies and of the utility of tumor budding beyond colorectal carcinoma to allow for wide spread implementation of this marker into routine surgical pathology reports in other areas of the gastrointestinal tract. However, it must be stressed that this is not “just” a pathology issue but rather will require close collaboration between pathologists, surgeons, and oncologists to further validate potential applications of this inexpensively assessed and powerful pathologic parameter.

References

  1. 1.

    Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299–311.

    Article  Google Scholar 

  2. 2.

    Imai T. The growth of human carcinoma: a morphological analysis. Fukuoka Igaku Zasshi. 1954;45:72–102.

    Google Scholar 

  3. 3.

    Brabletz T, Jung A, Reu S, et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. PNAS. 2001;98:10356–61.

    CAS  Article  Google Scholar 

  4. 4.

    Smedt L, Palmans S, Andel D, et al. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br J Cancer. 2016;116:58–65.

    Article  Google Scholar 

  5. 5.

    Yamada N, Sugai T, Eizuka M, et al. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition. Hum Pathol. 2017;60:151–9.

    CAS  Article  Google Scholar 

  6. 6.

    Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.

    Article  Google Scholar 

  7. 7.

    Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627–35.

    CAS  Article  Google Scholar 

  8. 8.

    Ueno H, Murphy J, Jass J, et al. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32.

    CAS  Article  Google Scholar 

  9. 9.

    Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385–94.

    Article  Google Scholar 

  10. 10.

    Karamitopoulou E, Zlobec I, Born D, et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer. 2013;49:1032–9.

    CAS  Article  Google Scholar 

  11. 11.

    Nakamura T, Mitomi H, Kikuchi S, et al. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology. 2005;52:1432–5.

    PubMed  Google Scholar 

  12. 12.

    Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33:134–41.

    CAS  Article  Google Scholar 

  13. 13.

    Puppa G, Senore C, Sheahan K, et al. Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology. 2012;61:562–75.

    Article  Google Scholar 

  14. 14.

    Giger O, Comtesse S, Lugli A, et al. Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol. 2012;25:1048–53.

    Article  Google Scholar 

  15. 15.

    Koelzer V, Zlobec I, Lugli A. Tumor budding in colorectal cancer—ready for diagnostic practice? Hum Pathol. 2016;47:4–19.

    Article  Google Scholar 

  16. 16.

    Nivatvongs S, Rojanasakul A, Reiman HM, et al. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum. 1991;34:323–8.

    CAS  Article  Google Scholar 

  17. 17.

    Nascimbeni R, Burgart LJ, Nivatvongs S, et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum. 2002;45:200–6.

    Article  Google Scholar 

  18. 18.

    Toh E-W, Brown P, Morris E, et al. Area of submucosal invasion and width of invasion predicts lymph node metastasis in pT1 colorectal cancers. Dis Colon Rectum. 2015;58:393–400.

    Article  Google Scholar 

  19. 19.

    Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol. 2004;39:534–43.

    Article  Google Scholar 

  20. 20.

    Wang H-S, Liang W-Y, Lin T-C, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum. 2005;48:1182–92.

    Article  Google Scholar 

  21. 21.

    Pai RK, Chen Y, Jakubowski MA, et al. Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. Mod Pathol. 2016;30:113–22.

    Article  Google Scholar 

  22. 22.

    Tsuruta O, Tsuji Y, Kawano H, et al. Indication for endoscopic resection of submucosal colorectal carcinoma: special reference to lymph node metastasis. Diagn Ther Endosc. 2000;6:101–9.

    CAS  Article  Google Scholar 

  23. 23.

    Kawachi H, Eishi Y, Ueno H, et al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study. Mod Pathol. 2015;28:872–9.

    Article  Google Scholar 

  24. 24.

    Bosch S, Teerenstra S, Wilt J, et al. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy. 2013;45:827–41.

    Article  Google Scholar 

  25. 25.

    Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2017; Epub ahead of print.

  26. 26.

    Edge SB, Byrd DR, Compton CC. Colon and rectum. In: Edge SB, Byrd DR, Compton CC, editors. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010. p. 143–64.

  27. 27.

    Betge J, Kornprat P, Pollheimer M, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19:3706–12.

    Article  Google Scholar 

  28. 28.

    Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Dis. 2014;16:259–64.

    Article  Google Scholar 

  29. 29.

    Petrelli F, Pezzica E, Cabiddu M, et al. Tumour budding and survival in stage II colorectal cancer: a systematic review and pooled analysis. J Gastrointest Cancer. 2015;46:212–8.

    CAS  Article  Google Scholar 

  30. 30.

    Rogers A, Gibbons D, Hanly A, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014;27:156–62.

    Article  Google Scholar 

  31. 31.

    Zlobec I, Hädrich M, Dawson H, et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br J Cancer. 2013;110:1008–13.

    Article  Google Scholar 

  32. 32.

    Zlobec I. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol. 2010;16:4823–31.

    CAS  Article  Google Scholar 

  33. 33.

    Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus. 2004;17:333–7.

    CAS  Article  Google Scholar 

  34. 34.

    Koike M, Kodera Y, Itoh Y, et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Ann Surg Oncol. 2008;15:1977–82.

    Article  Google Scholar 

  35. 35.

    Nakanishi Y, Ohara M, Doumen H, et al. Correlation between tumor budding and post-resection prognosis in patients with invasive squamous cell carcinoma of the thoracic esophagus. World J Surg. 2011;35:349–56.

    Article  Google Scholar 

  36. 36.

    Miyata H, Yoshioka A, Yamasaki M, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer. 2009;115:3324–34.

    Article  Google Scholar 

  37. 37.

    Teramoto H, Koike M, Tanaka C, et al. Tumor budding as a useful prognostic marker in T1‐stage squamous cell carcinoma of the esophagus. J Surg Oncol. 2013;108:42–46.

    Article  Google Scholar 

  38. 38.

    Jesinghaus M, Boxberg M, Konukiewitz B, et al. A novel grading system based on tumor budding and cell nest size is a strong predictor of patient outcome in esophageal squamous cell carcinoma. Am J Surg Pathol. 2017;41:1112–20.

    Article  Google Scholar 

  39. 39.

    Weichert W, Kossakowski C, Harms A, et al. Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma. Eur Respir J. 2016;47:938–46.

    CAS  Article  Google Scholar 

  40. 40.

    Boxberg M, Jesinghaus M, Dorfner C, et al. Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system. Histopathology. 2017;70:1125–37.

    Article  Google Scholar 

  41. 41.

    Thies S, Guldener L, Slotta-Huspenina J, et al. Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas. Hum Pathol. 2016;52:1–8.

    Article  Google Scholar 

  42. 42.

    Smyth E, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–v49.

    CAS  Article  Google Scholar 

  43. 43.

    Gulluoglu M, Yegen G, Ozluk Y, et al. Tumor budding is independently predictive for lymph node involvement in early gastric cancer. Int J Surg Pathol. 2015;23:349–58.

    CAS  Article  Google Scholar 

  44. 44.

    Olsen S, Linda J, Fields RC, et al. Tumor budding in intestinal type gastric adenocarcinoma is associated with nodal metastasis and recurrence. Hum Pathol. 2017;68:26–33.

    CAS  Article  Google Scholar 

  45. 45.

    Che K, Zhao Y, Qu X, et al. Prognostic significance of tumor budding and single cell invasion in gastric adenocarcinoma. Onco Targets Ther. 2017;10:1039–47.

    CAS  Article  Google Scholar 

  46. 46.

    Ohike N, Coban I, Kim GE, et al. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol. 2010;34:1417.

    Article  Google Scholar 

  47. 47.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

    Article  Google Scholar 

  48. 48.

    O’Connor K, Li-Chang HH, Kalloger SE, et al. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2015;39:472.

    Article  Google Scholar 

  49. 49.

    Kohler I, Bronsert P, Timme S, et al. Detailed analysis of epithelial‐mesenchymal transition and tumor budding identifies predictors of long‐term survival in pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2015;30:78–84.

    CAS  Article  Google Scholar 

  50. 50.

    Karamitopoulou E, Haemmig S, Baumgartner U, et al. MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. Mod Pathol. 2017;30:1116–25.

    CAS  Article  Google Scholar 

  51. 51.

    Wartenberg M, Zlobec I, Perren A, et al. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma. Oncotarget. 2015;6:4190–201.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kyra B Berg.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Berg, K.B., Schaeffer, D.F. Tumor budding as a standardized parameter in gastrointestinal carcinomas: more than just the colon. Mod Pathol 31, 862–872 (2018). https://doi.org/10.1038/s41379-018-0028-4

Download citation

Further reading